iTeos Therapeutics launched to develop immunomodulators
New Company to Focus on Developing Novel Immunotherapy Compounds for Cancer Treatment
07-May-2012 -
The Ludwig Institute for Cancer Research (LICR) announced the launch of a private biotechnology enterprise, iTeos Therapeutics SA, to develop a pre-clinical pipeline of immunomodulators to stimulate the immune system’s ability to attack cancer. Founded by LICR with the de Duve Institute at the ...
cancer
immunomodulators
immunotherapies